Uwe Scherf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Uwe Scherf has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Adrienne Hall
U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD, 21702, USA
1 shared publication- Christopher P. Stefan
Diagnostic Systems Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland
1 shared publication - Dayanara Lebron Aldea
Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, CA, 94551, USA
1 shared publication Eneida Hatcher
National Center for Biotechnology Information, National Library of Medicine, 8600 Rockville Pike, Bethesda, MD, 20894, USA
1 shared publication- Heike Sichtig
U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA
1 shared publication Jeffrey Koehler
U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD, 21702, USA
1 shared publication
Latest Publications
- Open Access
- 25 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
FDA-ARGOS is a database with public quality-controlled reference genomes for diagnostic use and regulatory science
FDA proactively invests in tools to support innovation of emerging technologies, such as infectious disease next generation sequencing (ID-NGS). Here, we introduce FDA-ARGOS quality-controlled reference genomes as a public database for diagnostic purposes and demonstrate its utility on the example of two use cases. We provide quality control metrics for the FDA-ARGOS genomic database resource and outline the need for genome quality gap filling in the public domain. In the first use case, we show more accurate microbial identification of Enterococcus avium from metagenomic samples with FDA-ARGOS reference genomes compared to non-curated GenBank genomes. In the second use case, we demonstrate the utility of FDA-ARGOS reference genomes for Ebola virus target sequence comparison as part of a composite validation strategy for ID-NGS diagnostic tests. The use of FDA-ARGOS as an in silico target sequence comparator tool combined with representative clinical testing could reduce the burden for completing ID-NGS clinical trials.
- 25 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
Open AccessFDA-ARGOS is a database with public quality-controlled reference genomes for diagnostic use and regulatory science
FDA proactively invests in tools to support innovation of emerging technologies, such as infectious disease next generation sequencing (ID-NGS). Here, we introduce FDA-ARGOS quality-controlled reference genomes as a public database for diagnostic purposes and demonstrate its utility on the example of two use cases. We provide quality control metrics for the FDA-ARGOS genomic database resource and outline the need for genome quality gap filling in the public domain. In the first use case, we show more accurate microbial identification of Enterococcus avium from metagenomic samples with FDA-ARGOS reference genomes compared to non-curated GenBank genomes. In the second use case, we demonstrate the utility of FDA-ARGOS reference genomes for Ebola virus target sequence comparison as part of a composite validation strategy for ID-NGS diagnostic tests. The use of FDA-ARGOS as an in silico target sequence comparator tool combined with representative clinical testing could reduce the burden for completing ID-NGS clinical trials.